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1. Introduction 
Hepatocellular carcinoma (HCC) is the most common primary liver cancer and is associated 
with high resistance to drugs and high mortality. There are multiple factors that influence its 
molecular pathogenesis but two well established characteristics of malignant transformation 
in HCC are its hypervascular nature and the upregulation of the Raf/MEK/ERK signaling 
cascade. MAPK pathway activation can be triggered by important risk factors of 
hepatocarcinogenesis such as HBV or HCV infection. Furtermore, its deregulation is well 
documented in human HCC patients and is associated with poor prognosis (Bruix & Llovet, 
2009). Constitutive stimulation of both ERK isoforms has been frequently observed in both 
HCC samples and hepatocarcinoma-derived cell lines and plays a prominent role in the 
proliferation, invasion and metastasis of HCC cells (Min et al., 2010). These processes are 
also associated with neoangiogenesis and aberrant vessel formation, which in turn depend 
on the development of hypoxic regions and VEGF overexpession frequently observed in 
tumor samples (Rosmorduc & Housset, 2010). The master regulators of the cellular response 
to oxygen deprivation are the hypoxia inducible transcription factors (HIFs). Their 
activation results in expression of many genes that contribute to survival and proliferation 
of malignant cells and, more importantly, resistance to conventional treatments and poor 
patient outcome (Poon, E. et al., 2009). Interestingly, hypoxia has been observed to lead to 
ERK activation, which can further stimulate HIF transcriptional activity. This can result in 
increased expression of HIF target genes that include pro-angiogenic factors and other 
proteins that facilitate adaptation of tumor cells to their environment (Dimova et al., 2009). 
In this chapter, we will discuss the cross-talk between these pathways, their contribution to 
HCC development and progression and their potential as targets of combined therapeutic 
approaches.  
2. Hepatocellular carcinoma 
Hepatocellular Carcinoma (HCC) is the fifth most common and third in lethality cancer. It is 
characterized by intrinsic drug-metabolizing activity that confers resistance to 
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chemotherapeutic treatment. Mortality is associated with metastasis, recurrence and new 
tumor development and diagnosis is usually made at intermediate or late stage so that only 
~ 20% of cases can undergo surgery that includes resection, ablation or transplantation. 
Unfortunately, due to the genomic heterogeneity of HCC tumors, the exact molecular 
pathogenetic and oncogenic alterations that lead to HCC initiation and progression are not 
completely understood and require further investigation. However, there are several risk 
factors and pathways known to be associated with the occurrence and development of this 
type of cancer (Villanueva et al., 2010). 
Probably the most important predisposing factor for the development of HCC is liver cirrhosis 
that usually results from viral infection (HBV or HCV), alcohol abuse or contamination with 
Aflatoxin B1. Other contributing factors include inflammation and non-alcoholic fatty liver 
disease (NAFLD). All of these factors can lead to HCC development by triggering cellular 
events such as proto-oncogene activation, ROS generation and genetic alterations or instability 
(Frau et al., 2010). Genetic studies of human HCCs resulted in the identification of gene 
mutations and expression profile alterations. The identified deregulated genes can be 
associated with important signaling pathways and shed more light in the molecular events 
that contribute to HCC pathogenesis. According to these analyses, there are three subgroups of 
human HCC cancers, genetic profile of which corresponds to the deregulation of specific 
signaling events (Hoshida et al., 2010). One of them is characterized by over-expression of 
growth factors (EGF, IGF II and HGF being the most prominent) and induction of major 
signaling pathways such as PI3K/AKT/mTOR and RAS/RAF/MAPK, which affect cell 
proliferation and survival and, moreover, contribute to the aggressive phenotype of the 
disease. In another subgroup, the affected genes are related to cell differentiation and liver 
development. These genes are found downstream of the WNT or the highly similar Hedgehog 
pathway and their involvement in human hepatocarcinogenesis is still under investigation. 
Whereas, in the third less-defined group, the early stages of the disease are linked to 
inflammation-related pathways, with interleukin-6 being a major signaling molecule 
(Villanueva et al., 2010; Zender et al., 2010). However, all these signaling pathways do not 
function independently in the context of HCC tumors but they cooperate and influence one 
another contributing to the progression of the disease. 
From these and other studies it has been made clear that ERK pathway activation and neo-
angiogenesis are two characteristics of HCCs that greatly facilitate malignant 
transformation, as they are involved in tumor development, growth and metastasis. 
Another aspect of HCC, common to many solid tumors, is the creation of hypoxic areas as a 
result of increased metabolic rate, irregular angiogenesis and tissue inflammation 
(Rosmorduc & Housset, 2010). The central regulatory elements of cell response to oxygen 
deprivation are the hypoxia inducible transcription factors (HIFs). After their activation, 
HIFs induce the expression of their targets, which in their turn facilitate adaption of the cells 
to the hypoxic environment of the tumor and contribute to survival, proliferation and 
aggressiveness of cancer cells.  
3. ERK pathway and HCC 
Extracellular-signal regulated kinases 1 and 2 (ERK 1/2 or else p44/42 MAPK) are 
serine/threonine protein kinases both homologous and highly similar in their regulatory 
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mechanisms and functions. They are expressed in all cell types and they integrate 
extracellular signals such as growth factors and cytokines into cellular responses that 
promote gene expression, proliferation, survival and migration. ERK activation relies on the 
binding of ligands to cell membrane receptors and the subsequent activation of the 
RAS/RAF/MEK signaling cascade resulting in the phosphorylation and activation of 
ERK1/2 (Pearson et al., 2001). It is well documented that sustained ERK activity is important 
for the development of many types of tumors including hepatocellular carcinoma. As it has 
been already mentioned, there is activation of Ras pathway and significant increase of 
phosphorylated ERK levels in all HCC-derived cell lines. However, Ras mutations that 
could account for sustained pathway activation are rare in human HCCs (Min et al., 2010). 
One explanation for constistutive ERK activation in HCCs can be that HBV or HCV viral 
infection interferes and activates the ERK signaling cascade facilitating thus 
hepatocarcinogenesis (Chin et al., 2007; Zhao et al., 2005). Another reason may lie with the 
fact that there is global suppression of negative regulators that control the ERK signaling 
cascade in HCC cell lines. It has been shown that Ras inhibitors are inactivated in HCC-
derived cell lines probably as a result of deregulated methylation and genomic instability 
(Calvisi et al., 2006). Furthermore, the Raf kinase inhibitor protein (RKIP) has been observed 
to be downregulated in HCC cells (Lee, H.C. et al., 2006). Significant decrease has also been 
detected in the phosphatase DUSP1, which restrains ERK activity by dephosphorylation, as 
a result of ubiquitin-mediated proteolysis triggered by sustained ERK activation in HCC 
(Calvisi et al., 2008).  
The constitutive activation of ERK signaling is essential for cell survival, proliferation and 
invasion of human HCC cells since Ras pathway inhibition results in growth suppression 
and cell death. Moreover, siRNA-mediated silencing of ERK2 or elimination of ERK1/2 
phosphorylation by silencing of MEK1 resulted in inhibition of cell proliferation and 
tumor growth suppression in xenograft animal models (Bessard et al., 2008; Gailhouste et 
al., 2010). Activation of the Raf/MEK/ERK pathway in human HCC biopsy samples can 
be used as a biomarker of the disease because nuclear phosphorylated ERK levels are 
higher in tumor samples (Abou-Alfa et al., 2006). Finally, ERK pathway activation is 
associated with poor patient outcome whereas, inversely, elevated expression levels of 
pathway inhibitors such as DUSP1 are observed in tumor samples of patients with longer 
survival time (Calvisi et al., 2008). 
The importance of the ERK pathway for HCC occurrence and progression made it an 
important candidate for targeted therapeutic approaches as shown in case of sorafenib. 
Sorafenib, a multikinase inhibitor, impedes cell proliferation by targeting the 
Raf/MEK/ERK signaling cascade at the level of Raf kinase (for which it was originally 
developed) and also exhibits antiangiogenic properties by targeting the tyrosine kinase 
activities of the vascular endothelial growth factor receptor-2/-3 (VEGFR-2/-3) and the 
platelet derived growth factor receptor beta (PDGFR-ǃ) (Liu, L. et al., 2006; Wilhelm et al., 
2004). Sorafenib has been recently approved as the first effective systemic drug for treating 
advanced HCC showing a significant (almost 3 months) increase in patient survival. Also, 
due to its tolerability in single agent trials, it has been evaluated in combination with other 
anticancer therapies, including cytotoxic chemotherapy and anti-angiogenic therapy (Llovet 
et al., 2008). The effectiveness of sorafenib in clinical evaluation highlights the potential of 
targeting the ERK pathway in the treatment of HCC. Recent experimental studies have 
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shown that treatment with MEK inhibitors (AZD6244, PD0325901) inhibited cancer cell 
proliferation and tumor growth in human HCC cell lines and HCC xenografts in animal 
models (Hennig et al., 2010; Huynh et al., 2007). Moreover, when AZD6244 was tested in 
combination with sorafenib, it enhanced the anti-tumor activity of sorafenib, suggesting the 
potential value of ERK pathway inhibition in combinational therapeutic approaches (Huynh 
et al., 2010). 
4. Angiogenesis and HCC 
HCC progression requires the development and maintenance of adequate blood supply. 
This requires vascular endothelial cell proliferation and migration in order to establish a 
new vascular network. The transformation from a poorly vascular nodule to the 
hypervascular malignant phenotype of the disease has become a hallmark for diagnosis, 
treatment and possible future therapeutic approaches (Fernandez et al., 2009). Formation of 
new vessels with abnormal architecture is linked to fibrinogenesis and cirrhosis, processes 
that cause extensive cell damage and can lead to malignancy (Rosmorduc & Housset, 2010). 
The ability to form new vessels is critical not only for the emergence of HCC but also for the 
growth of metastatic nests and the transition from early to advanced stages of the disease. 
Indeed, impairing the blood supply that feeds the tumor with transarterial 
chemoembolization is an effective treatment for patients with advanced HCC and improves 
their survival (Llovet & Bruix, 2003).  
Neoangiogenesis in HCC is a process stimulated by hypoxia, growth factors, oncogenes and 
nutrient concentration followed by the release of pro-angiogenic growth factors and 
activation of endothelial cells. The most prominent pro-angiogenic signal, as revealed in a 
number of studies, is vascular endothelial growth factor (VEGF) (Fernandez et al., 2009; 
Rosmorduc & Housset, 2010). Its expression can be induced as a result of hypoxia, 
oncogenic signaling and viral infection, involving MAPK pathway activation and 
transcriptional regulation by AP1 and HIF-1ǂ (Hassan et al., 2009). Its significant role in 
HCC is shown by the fact that cells isolated from human tumors are able to produce VEGF 
by themselves. Hypoxia further enhances VEGF expression both by regulation at the 
transcriptional level and by stabilization of VEGF mRNA (von Marschall et al., 2001). 
Moreover, VEGF and its receptors (VEGFR-1 and VEGFR-2) are found over-expressed in 
patients’ samples and their increased levels have been associated with the aggressive 
phenotype of the disease (Imura et al., 2004). In line with this observation, increased 
concentration of VEGF in serum samples is directly connected to poor patient outcome after 
resection or ablation (Poon, R.T. et al., 2004; Poon, R.T. et al., 2007).  
Other factors that promote tumor angiogenesis in HCC are FGFs (Fibroblast growth factors), 
angiopoietins (Ang-2) and platelet-derived growth factor (PDGF). There is evidence that 
bFGF over-expression is involved in vascular endothelial cell proliferation during tumor 
angiogenesis in human HCC (Imura et al., 2004). Furthermore, Ang-2 levels as well as its 
activity through the Tie-2 receptor are increased in human samples and have been 
correlated with neovascularization and microvessel density (MVD) (Mitsuhashi et al., 2003). 
Finally, animal studies have shown that the involvement of PDGF-C in HCC development is 
linked to its role in the initiation of fibrosis (Campbell et al., 2005). Interestingly, it appears 
that all these factors team up with the VEGF signaling cascade in order to provoke normal 
or aberrant vessel formation in HCCs. 
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Since vascular formation is very important for tumor progression and transition to 
malignancy, it represents an intriguing therapeutic target for the treatment of HCC. At 
present, there are several drugs undergone investigation in experimental models or humans 
and some of them are already in use in various types of cancer. Most of the tested inhibitors 
target selectively the VEGF pathway and induce arrest of endothelial cell proliferation, 
regression of the existing vessels or suppress the mobilization of endothelial progenitor cells 
from bone marrow. These agents range from monoclonal antibodies (mAb) targeting VEGF-
A, like bevacizumab (Avastin), to small molecules that inhibit autophosphorylation of VEGF 
receptors like sorafenib (Nexavar), the single agent that was approved for the treatment of 
advanced hepatocellular carcinoma in 2007 (Fernandez et al., 2009). 
5. Hypoxia and HCC  
As many other solid tumors, HCC is characterized by the development of hypoxia. Even in 
normal liver, emergence of hypoxic conditions can result from its division into areas with 
different capabilities of oxygen delivery (i.e., 60 to 65 mmHg in the portal area to 30 to 35 
mmHg in the perivenous area) and increased cellular metabolic activity, which leads to high 
oxygen consumption (Rosmorduc & Housset, 2010). Apart from that, the response to trauma 
or inflammation can cause aberrant vessel formation, irregular blood flow and, finally, poor 
oxygenation of the cells. Cells respond to oxygen deprivation by activating a number of 
genes that allow them to adapt and survive. More importantly, hepatocellular carcinoma 
cells not only survive but also show significant stimulation of their proliferation under 
hypoxia as opposed to other cancer cell lines (Gwak et al., 2005).  
Hypoxia promotes tumor progression through several mechanisms. Under hypoxic 
conditions, cells shift their metabolism from oxidative phosphorylation to anaerobic 
glycolysis by the induction of genes that encode glucose transporters, glycolytic enzymes 
and proteins that remove glycolysis by-products (e.g. lactic acid) from cancer cells. As 
mentioned above, HCC tumors exhibit epigenetic alterations and signaling pathways 
activation that stimulate proliferation. These may be supported by tumor hypoxia, which 
affects the methylation status of HCC cells and, more importantly, activates the ERK 
pathway (Liu, Q. et al., 2011; Minet et al., 2000). Another very important contribution of 
hypoxia to HCC development is the stimulation of angiogenesis. Two of the central pro-
angiogenic factors in HCC, namely VEGF and angiopoietin 2, are induced in hypoxic 
conditions and promote the abnormal vessel formation and branching observed in these 
tumors. Key mediators of these responses and central components of hypoxia signaling 
within the cell are the hypoxia inducible factors (HIFs). 
HIFs are heterodimeric transcriptional complexes that respond to changes of cellular oxygen 
concentration and activate the expression of hypoxia target genes. These genes encode for 
proteins involved in processes critical for oncogenesis such as survival, proliferation, 
invasion and metastasis. Active HIF heterodimers are composed of the constitutively 
expressed HIF-ǃ subunit (or ARNT; Aryl hydrocarbon Receptor Nuclear Translocator) and 
the regulated HIF-ǂ subunit, which is over-expressed in many tumors and causes HIF 
activation and increased transcription of its targets (Semenza, 2010). HCC is not an 
exception and expression levels of HIF-1ǂ are increased in all stages of the disease and 
correlate to its progress.  
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There is plenty of evidence linking HIF-1ǂ to both early and late HCC stages. The genetic 
instability observed during the premalignant state of HCC can be caused by viral infection. 
HCV core protein induces HIF-1ǂ and HIF-dependent transcriptional activation of the 
VEGF gene in HCC-derived cells (Hassan et al., 2009). Liver angiogenesis has been indeed 
observed in biopsy samples of HCV patients and is possibly an essential step for HCV-
related oncogenesis. HIF-1ǂ mRNA and protein levels are also increased in premalignant 
dysplastic nodules, as observed in both human and animal samples,  and cause up-
regulation of a number of genes that promote angiogenesis (VEGF), glucose transport 
(GLUT1) and PI3K/AKT pathway activation (growth factor IGF-II and hepatocyte growth 
factor receptor c-Met) (Nakamura et al., 2007). Interestingly, it has also been shown that 
HIF-1ǂ expression at this stage is hypoxia-independent and its levels rise as the disease 
progresses (Tanaka et al., 2006). These findings indicate the important role of this 
transcription factor in abnormal gene expression that occurs during early HCC 
development.  
As already mentioned, hypervascularity is a prominent feature of progression to HCC 
malignancy and HIF-1ǂ over-expression is also directly associated with VEGF expression, 
microvessel density (MVD) and microvenous invasion in human HCC samples (Huang et 
al., 2005). Deregulation of the HIF pathway, which comes as a result of HIF-1ǂ over-
expression, is often associated with resistance to radiotherapy and chemotherapy, which 
renders hypoxic tumors highly aggressive and metastatic (Poon, E. et al., 2009). This is also 
true for primary HCC, in which HIF-1ǂ expression is associated with poor response to 
radiotherapy, metastasis and low survival rates (Xiang et al., 2011). Therefore, 
understanding HIF-ǂ regulation may provide valuable information in order to target the 
HIF pathway as a means for combinational therapeutic strategies against HCC. 
6. HIF-α structure and regulation   
Three HIF-ǂ isoforms have been so far identified: HIF-1ǂ, HIF-2ǂ and HIF-3ǂ. HIF-1ǂ and -
2ǂ have similar structure and are rapidly induced in response to hypoxia. The third family 
member is not well understood. It exists in several splice variants, one of which acts as a 
dominant negative regulator of HIF-dependent gene expression as it binds to the HIF-1ǂ 
subunit to form a nonfunctional complex. Whereas HIF-1ǂ shows broad tissue distribution, 
HIF-2ǂ is cell-type specific and was shown to have distinct biological roles. However, HIF-1 
and HIF-2 can regulate both overlapping and distinct target genes (Poon, E. et al., 2009). 
More specifically, liver cells express both isoforms, albeit, with different kinetic profiles: 
HIF-1ǂ responds quickly but returns to basal levels early. In contrast, HIF-2ǂ expression is 
delayed but prolonged, suggesting a coordinated response of the two subunits to hypoxia 
(Wiesener et al., 2003). 
Both HIF-1ǂ and HIF-2ǂ contain basic helix loop helix (bHLH) and PER-ARNT-SIM (PAS) 
domains in their NH2-terminal regions that mediate heterodimerization and binding to 
specific DNA regulatory sequences called hypoxia response elements (HREs) (Fig. 1). The 
PAS domain contains two conserved repeats termed PAS-A and PAS-B. In their C-
terminal regions, both contain transactivation domains (TAD) that mediate the 
transcription of their targets. Oxygen sensitivity and regulation relies in a structural 
feature called oxygen depended degradation (ODD) domain that lies inside the central 
region of HIF-ǂ (Semenza, 2003).  
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In terms of its oxygen-dependent or -independent regulation, HIF-1ǂ is more extensively 
investigated. HIF-2ǂ, on the other hand, is regulated in a similar fashion by oxygen but 
many elements of its oxygen-independent regulation still remain unclear. Under normal 
oxygen conditions, HIF-1ǂ is constantly produced and destroyed in a process that involves 
von Hippel-Lindau (VHL)-mediated polyubiquitination and subsequent proteasomal 
degradation (Schofield & Ratcliffe, 2005). Interaction of HIF-1ǂ with VHL, a tumor 
suppressor protein and a subunit of an E3 ubiquitin ligase complex, requires the 
hydroxylation of two proline residues within the ODD domain of HIF-1ǂ. This 
hydroxylation is mediated by three conserved prolyl hydroxylases (termed PHDs or HPHs), 
the activity of which depends on the availability of oxygen, iron and 2-oxoglutarate 
(Semenza, 2001). When oxygen becomes sparse, hydroxylation is impaired, HIF-1ǂ is 
stabilized and is imported into the nucleus, where it dimerizes with ARNT and activates the 
expression of its target genes. However, oxygen dependent-regulation does not only rely on 
HIF-1ǂ destruction alone but also on the control of its activity. Another oxygen-sensitive 
hydroxylase called FIH (Factor Inhibiting HIF-1) modifies HIF-1ǂ in one asparagine residue 
situated inside its C-terminal TAD region (Asn803) and interferes with the association of 
HIF-1ǂ with the transcriptional co-activator CBP/p300 (Lancaster et al., 2004a).  
Apart from oxygen tension, HIF-1ǂ expression and activity are additionally stimulated by 
oxygen-independent mechanisms that respond to oncogenic activation, growth factors, 
cytokines and variations of the cellular environment (e.g. pH). There are multiple levels at 
which cells can control HIF-1ǂ activity, ranging from transcriptional and translational 
regulation to post-translational modifications. Its transcriptional activation responds to 
inflammatory stimuli as IKKǃ activation causes increased HIF-1ǂ gene expression in a NF-
κB-dependent fashion in the liver of hypoxic mice (Rius et al., 2008). The signal transducer 
and activator of transcription 3 (Stat3) is also involved in the regulation of HIF-1ǂ mRNA 
synthesis (Niu et al., 2008) and mediates the transcriptional suppression of HIF-1ǂ by the 
eIF2ǂ kinase PKR (Papadakis et al., 2010). Activation of the phosphatidylinositol 3-
kinase/AKT pathway leads to elevated translation of HIF-1ǂ mRNA and increased HIF-1ǂ 
protein levels (Bardos & Ashcroft, 2005). Post-translationally, HIF-1ǂ is regulated either 
through its association with other proteins or its modification by number of different 
enzymes. Protein interactions like binding to the molecular chaperone HSP90 can increase 
HIF-1ǂ stability by inhibiting VHL-independent degradation (Isaacs et al., 2002; Katschinski 
et al., 2004). On the other hand, the protein RACK1 competes with HSP90 for binding to the 
HIF-1ǂ N-terminal PAS-A domain. The RACK1-HIF-1ǂ interaction, which is stabilized by 
the protein SSAT1 and inhibited by Sept9-v1, promotes increased ubiquitination and 
degradation of HIF-1ǂ irrespective of oxygen levels (Amir et al., 2009; Baek et al., 2007; Liu, 
Y.V. et al., 2007). MgcRacGAP (male germ cell RacGTPase Activating Protein), identified 
using the yeast two-hybrid system, is another protein that interacts with and inhibits HIF-
1ǂ. MgcRacGAP over-expression inhibits HIF-1ǂ transcriptional activity, without lowering 
HIF-1ǂ protein levels or altering its subcellular localization (Lyberopoulou et al., 2007).  
Apart from hydroxylation, other posttranslational modifications of HIF-1ǂ include 
SUMOylation, acetylation, S-nitrosylation and phosphorylation by a number of different 
kinases. HIF-1ǂ can be SUMOylated but the role of this modification remains 
controversial; certain reports claim that SUMO conjugate stabilizes HIF-1ǂ while others 
suggest that deSUMOylation of HIF-1ǂ is necessary for its stability and activity (Bae et al., 
2004; Berta et al., 2007; Carbia-Nagashima et al., 2007; Cheng et al., 2007). In contrast, 
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acetylation of HIF-1ǂ by the acetyltransferase ARD1 has a negative impact by facilitating 
its interaction with VHL (Jeong et al., 2002), although its effect on HIF-1ǂ stability has also 
been later disputed (Wei & Yu, 2007). Nitrogen oxide (NO) can interfere with PHD 
function as well as cause HIF-1ǂ S-nitrosylation, which can stabilize HIF-1ǂ in tumor-
associated macrophages (Li et al., 2007; Wei & Yu, 2007). 
Direct HIF-1ǂ phosphorylation can be an efficient way to rapidly and reversibly regulate 
HIF-1 activity in response to different stimuli. HIF-1ǂ phosphorylations can be activating, 
such as the one at Thr796 in the C-TAD domain of HIF-1ǂ that impairs his interaction with 
FIH-1 (Lancaster et al., 2004b). On the contrary, phosphorylation by glycogen synthase 
kinase 3 (GSK3) at three residues (Ser551/Thr555/Ser589) within the HIF-1ǂ N-TAD drives 
HIF-1ǂ to VHL-independent proteasomal degradation and down-regulates its activity 
(Flugel et al., 2007). We have recently described HIF-1ǂ phosphorylation by casein kinse 1 
(CK1) which also negatively affects HIF-1 activity (Kalousi et al., 2010). CK1δ targets Ser247 
in the PAS-B domain of HIF-1ǂ and does not affect its stability or localization but interferes 
with the ability of HIF-1ǂ to form an active complex with ARNT under hypoxia. Over-
expression of CK1δ inhibited, whereas, inhibition or silencing of CK1δ stimulated the 
activity of HIF-1 in several different cell lines, including hepatoma-derived cancer cells. 
Furthermore, inhibition of CK1 activity in HCC- cells (Huh7) resulted in significantly higher 
proliferation rates under hypoxia, highlighting the importance of HIF-1 activity for hypoxic 
adaptation and suggesting an anti-proliferative role for CK1δ (Kalousi et al., 2010). Others, 
recent but less characterized modifications of HIF-1ǂ include phosphorylation of Ser696 by 
ATM kinase and Ser576/Ser657 by Plk3, both of which activate HIF-1ǂ by stabilizing its 
protein levels (Cam et al., 2010; Xu et al., 2010). Finally, the longer known, best studied and 
probably most relevant to HCC direct phosphorylation of HIF-1ǂ is the one mediated by 
ERK (p44/42 MAPK), which will discussed extensively in the next section. 
Transcriptional activity of HIF-1ǂ ultimately depends on its nuclear accumulation. In order 
to enter the nucleus HIF-1ǂ uses more than one import pathways. The first one involves the 
presence of a classical bipartite-type nuclear localization signal (NLS) in the C-terminal part 
of HIF-1ǂ and interaction with importin ǂ to mediate its translocation to the nucleus 
(Depping et al., 2008; Kallio et al., 1998; Luo & Shibuya, 2001). Moreover, recent work from 
our lab has shown that HIF-1ǂ active transport through the nuclear pore complex can be 
mediated by multiple import receptors that, apart from importin ǂ family members, also 
include importins 4 and 7 (Chachami et al., 2009) . Interaction with importins 4 and 7 
involves the NH2-terminal part of HIF-1ǂ (amino acids 1-251), which also contains the 
bHLH and PAS-A domains, but the exact nature of the NLS that mediates their 
association is still unclear. The operation of more than one different pathways may ensure 
the fast and efficient translocation of HIF-1ǂ inside the nucleus as part of an effective 
cellular response to hypoxic stimuli (Fig. 1). However, the time that HIF-1ǂ spends inside 
the nucleus and, ultimately, its activity depends also on its nuclear export rate, which is 
mediated by the major mammalian exportin CRM1 and regulated by the Raf/MEK/ERK 
pathway (see below).  
7. ERK pathway and HIF-1α 
The MAPK pathway is one of the two best known major signal transduction pathways 
regulating HIF-1ǂ activity (the other is PI3K/AKT). Apart from being induced by growth 
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factors, cytokines and oncogenes, the MAPK pathway is also activated by hypoxia in several 
different cell lines including hepatoma HepG2 cells (Liu, C. et al., 2005; Minet et al., 2000; 
Mottet et al., 2002) and was suggested to affect both HIF-1ǂ mRNA translation and HIF-1 
transcriptional activity (Fukuda et al., 2002; Richard et al., 1999). This was shown by the use 
of MEK1 inhibitor PD98059 which decreased HIF-1-dependent gene expression in a number 
of cell lines including the hepatoma-derived Hep3B (Minet et al., 2000; Salceda et al., 1997). 
Also, studies from our own and other groups using Gal4-HIF-1ǂ fusion proteins have 
shown that the ERK pathway is involved in hypoxia-dependent HIF-1ǂ transactivation 
domain function in different cell lines (Lee, E. et al., 2002; Mylonis et al., 2006). Finally, HIF-
1ǂ can be directly phosphorylated by ERK (p44/p42 MAPK) both in vitro and in vivo but is 
not a direct target of the other MAPK family members (p38 or c-JNK) (Dimova et al., 2009). 
Although there had been efforts to identify the exact HIF-1ǂ sites phosphorylated by ERK, 
these remained unknown until quite recently. The issue was clarified by our recent work 
using in vitro phosphorylation assays, mass spectrometry and site directed mutagenesis, 
which led to the indentification of two conserved serine residues (Ser641 and Ser643) as the 
major ERK phosphorylation sites on HIF-1ǂ (Mylonis et al., 2006). Furthermore, inhibition of 
HIF-1ǂ phosphorylation by mutagenesis of the ERK target sites (conversion of both 
Ser641/Ser643 into Ala) or treatment with the ERK pathway inhibitor PD98059 impaired 
nuclear accumulation of HIF-1ǂ and, consequently, decreased its transcriptional activity. 
However, when cells expressing the phosphorylation-deficient mutant of HIF-1ǂ were 
treated with Leptomycin B (a specific inhibitor of CRM1-dependent nuclear export) nuclear 
localization of the mutant HIF-1ǂ was restored and its activity was partially recovered, 
suggesting that lack of ERK-depended phosphorylation reduces nuclear concentration of 
HIF-1ǂ by excessive nuclear export into the cytoplasm (Mylonis et al., 2006).  
These first results indicated that the mechanism by which ERK phosphorylation regulates 
HIF-1ǂ activity lies downstream of its synthesis and stabilization steps and involves 
regulated nucleocytoplasmic shuttling. However, this kind of regulation requires that HIF-
1ǂ possesses a nuclear export signal (NES) in addition to its NLS. We were, indeed, able to 
show the presence of such a signal in the form of an atypical hydrophobic NES 
(632MEDIKILI639), situated in close proximity to the serine residues 641/643 modified by 
ERK (Mylonis et al., 2008). This NES interacts strongly with CRM1 but only when ERK-
dependent phosphorylation of HIF-1ǂ is impaired. These data also support the idea that 
regulation of HIF-1ǂ nuclear shuttling is the major – if not exclusive – mechanism through 
which ERK-mediated phosphorylation controls HIF-1 activity since phospho-mimetic 
mutation of Ser641 into Glu or mutation of the NES renders the mutant form of HIF-1ǂ 
largely resistant to MAPK-pathway inhibition. Furthermore, the NES mutation 
“suppressed” the Ser641/Ser643Ala double mutation and HIF-1ǂ lacking both NES and 
ERK-sites regained wild-type properties in terms of localization and activity (Mylonis et al., 
2008). Taken together, our data, which were also confirmed in a hepatoma-derived cell line 
(Huh7), support the following model, also shown in Fig. 1. After stabilization, HIF-1ǂ 
interacts with multiple nuclear import receptors (importins ǂ/ǃ, 4 and 7) and is transported 
into the nucleus through the nuclear pore compexes (NPCs). Once in the nucleoplasm and 
with the HIF-1ǂ NES exposed, there are two possible scenarios. If the MAPK/ERK pathway 
is inactive, as in a quiescent cell, CRM1 will bind to the NES and return HIF-1ǂ to the 
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cytoplasm, keeping, thus, its nuclear concentration and subsequent activity low. However, if 
ERK is active (in response to hypoxia or other oncogenic stimuli), it will phosphorylate HIF-
1ǂ and mask its NES, thereby trapping HIF-1ǂ inside the nucleus, promoting its 
accumulation and maximizing its activity. Subsequent interaction with ARNT will form an 
active HIF-1 heterodimer, which can bind to DNA and stimulate transcription. This model 
does not exclude the possibility that ERK-mediated phosphorylation has additional, albeit 
minor, effects on HIF-1ǂ regulation such as promoting interaction of phosphorylated HIF-1ǂ 
with another nuclear factor or stimulating the activity of HIF-1ǂ partners such as CBP/p300 
(Sang et al., 2003).  
 
Fig. 1. HIF-1ǂ regulation by ERK-mediated phosphorylation.  
This schematic model shows how nucleocytoplasmic shuttling and activity of HIF-1ǂ is 
controlled by ERK. HIF-1ǂ is transported into the nucleus by nuclear import receptors 
(importins ǂ/ǃ, 4 and 7) but also contains an NES. In the absence of modification by ERK, 
binding of CRM1 to the NES returns HIF-1ǂ to the cytoplasm and limits its activity by 
shortening its intranuclear resident time. When ERK phosphorylates HIF-1ǂ, the NES is 
masked, interaction with CRM1 is inhibited and HIF-1ǂ is allowed to accumulate inside the 
nucleus and attain maximal activity by forming an active HIF-1 heterodimer with ARNT 
and binding to DNA to stimulate transcription (see text for relevant references).  
The link between ERK and HIF-1 appears not to be unidirectional. Many reports have 
shown that hypoxia induces the expression of several members of the DUSP (dual 
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specificity phosphatase also called MAPK phosphatase, MKP) family, which inactivate the 
MAPKs, including ERK, by dephosphorylation (Bermudez et al., 2011; Bernaudin et al., 
2002; Laderoute et al., 1999; Liu, C. et al., 2005; Seta et al., 2001). Expression of DUSP1 in 
HepG2 cells may be the reason for the loss of ERK activation after prolonged exposure to 
hypoxia (Liu, C. et al., 2005), suggesting that hypoxia-inducible DUSPs may play a critical 
role in the spatio-temporal regulation of MAPK signaling. Furthermore, HIF-1 is itself 
required for the induction of DUSP6 (Bermudez et al., 2011), suggesting the operation of the 
negative feedback loop shown in Fig. 2. Since excessive and prolonged activation of ERK or 
HIF-1 may lead to apoptosis (Cagnol et al., 2006; Carmeliet et al., 1998), this negative 
feedback may act to limit ERK and, consequently, HIF-1ǂ activity to a threshold compatible 
with cell survival and proliferation under hypoxia. On the other hand, HIF-1 has been 
recently shown to inhibit DUSP2 transcription causing DUSP2 suppression and prolonged 
phosphorylation of ERK, which increased chemoresistance and malignancy in human 
cancer cells under hypoxia (Lin et al., 2011). This suggests the additional operation of a feed-
forward (or positive feedback) loop (also shown in Fig. 2) that can explain the down-
regulation of DUSP2 and parallel elevation of ERK and HIF-1 activity in hypoxic cancer 
cells. It is, however, ambiguous the fact that hypoxic DUSP2 suppression was not observed 
in hepatoma cell lines and clinical samples of cancerous liver had similar levels of DUSP2 
mRNA as those derived from normal tissue (Lin et al., 2011) suggesting limited and tissue-
specific relevance of this mechanism. 
This tight connection between ERK activity and HIF-1ǂ can be targeted for controlling 
HIF-1 activity (Fig. 2). Indeed, nuclear accumulation and activity of HIF-1ǂ was impaired 
when cancer cells were treated with natural occurring compounds such as flavonoids that 
inhibit the MAPK pathway and ERK-dependent HIF-1ǂ phosphorylation (Triantafyllou et 
al., 2008). Moreover, the transient expression of a 43 amino acid HIF-1ǂ peptide that 
contains the ERK modification sites  and can be itself an ERK substrate (termed MTD: 
MAPK target domain) caused nuclear exclusion and loss of activity of endogenous HIF-1ǂ 
(Mylonis et al., 2008). Finally, we have recently shown that the flavonoid kaempferol 
could act as a potent inhibitor of hepatoma cancer (Huh7) cell viability by inhibiting ERK 
activation and causing cytoplasmic mislocalization and inactivation of HIF-1ǂ (Mylonis et 
al., 2010). Kaempferol could play a dual role in impairing cancer cell growth. It exhibited a 
mild effect on Huh7 cell survival under normal oxygen concentration, most likely due to 
inhibition of the MAPK pathway, which is critical for cell proliferation. However, 
kaempferol exerted a much stronger negative effect under hypoxia, apparently by 
additionally blocking HIF-1 activity required for cell viability at 0.1 - 1% O2, conditions 
that are physiologically more relevant to those inside a tumor growing in vivo. This 
provided proof-of-principle for the potential use of kaempferol or other HIF-1ǂ 
phosphorylation inhibitors as anti-HCC agents, since they could selectively target cancer 
cells normally exposed to hypoxia. The potential of kaempferol to inhibit both ERK and 
HIF-1 was at low μΜ concentration (IC50 close to 5 μΜ), which falls within the plasma 
flavonoid concentration range achievable by dietary intake alone (Gates et al., 2007; 
Manach et al., 2005). As a naturally occurring dietary substance without known side 
effects, kaempferol could be a good candidate for further evaluation, as chemopreventive 
or therapeutic compound, in controlled prospective studies of HCC patients along or in 
combination with other established conservative and interventional therapies.  
www.intechopen.com
 
Hepatocellular Carcinoma – Basic Research 
 
264 
   
Fig. 2. The hypoxia-ERK-HIF-angiogenesis axis, feedback regulations and possible sites of 
targeted intervention.  
HIF-1ǂ, induced by hypoxia and activated by ERK-mediated phosphorylation, stimulates 
the production of VEGF that promotes angiogenesis. Induction of DUSP6 (and possibly 
other DUSPs, not shown) by HIF-1 deactivates ERK as a negative feedback mechanism, 
while suppression of DUSP2 can be part of an opposing feed-forward mechanism (not 
occurring in liver cells). This circuitry can be interrupted by agents that inhibit ERK 
activation (such as sorafenib and kaempferol), block HIF-1ǂ phosphorylation (such as MTD) 
or impair VEGF function (such as sorafenib and bevacizumab). For further details and 
relevant reference see text. 
8. Targeting the HIF pathway in HCC 
Induction of the HIF- pathway may not come as a result of the cancer alone, but it can also 
be attributed to conventional HCC treatment such as chemoembolization which has been 
widely used in unresectable cases of hepatocellular carcinoma (Llovet & Bruix, 2003). 
However, restriction of the blood flow in the treated tissue generates hypoxic conditions 
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and activation of the HIF pathway, which may lead to a phenotypic change that renders 
cancer cells more invasive and metastatic, with subsequent failure of treatment as shown in 
animal primary liver cancers (Patsenker et al., 2009). Therefore, suppression of HIF-1 
activity can be especially beneficial when combined with conventional treatments or future 
therapeutic agents that target other pathways related to HCC. This is already evident in 
experimental models, in which inhibition of HIF-1ǂ expression enhanced the efficacy of 
doxorubicin in suppressing HCC cell growth through stimulation of apoptosis and down-
regulation of VEGF (Liu, F. et al., 2008).  
Cell based methods have been used to screen for HIF-1 inhibitors and many small molecules 
have been identified that impair cancer cell growth by reducing HIF-1ǂ protein levels – 
through blocking its expression or enhancing its degradation – or by impairing its 
transcriptional activity (Semenza, 2010; Wilson & Hay, 2011). Another novel method to 
identify HIF-1 inhibitors is screening, recognition and isolation of new bioactive compounds 
from natural sources with molecularly imprinted polymers (MIPs), which have been 
developed using as templates known compounds that interfere with HIF-1 activity (Lakka et 
al., 2011). Of course, the potential application of these agents in cancer therapy relies on the 
outcome of clinical trials. However, the search for HIF-1 inhibitors revealed that several 
already tested and established anti-cancer drugs such as topotecan, a topoisomerase 
inhibitor, geldanamycin, an HSP90 inhibitor, and trichostatin A, a histone deacetylase 
inhibitor, can also block HIF-1 activity (Ibrahim et al., 2005; Poon, E. et al., 2009; Rapisarda et 
al., 2004). Given the ERK-HIF connection, extensively discussed above, another way to 
suppress HIF-1 would be to inhibit the Raf/MEK/ERK signaling pathway. The approval of 
sorafenib, a Raf inhibitor and anti-angiogenic agent, as single agent against HCC probably 
demonstrates this principle. Although, the effect of sorafenib on HIF-1 activity has not been 
directly studied in HCC, sorafenib has been shown to interfere with the HIF pathway in 
models of melanoma and neuroblastoma (Kumar et al., 2007; Nilsson et al., 2010). It is 
possible that combination of sorafenib with other agents that also target ERK (such as 
kaempferol or other naturally occurring substances with similar properties), HIF-1ǂ (such as 
MTD) or VEGF (such as bevacizumab or inhibitors of the VEGF receptor) could be more 
efficient in treating HCC and preventing acquirement of resistance (Fig. 2).  
9. Conclusion 
Aberrant angiogenenesis, MAPK pathway activation and hypoxia contribute to the 
aggressiveness of hepatocellular carcinoma. This property is further enhanced by the fact 
that these processes positively influence one another in a way that adds up to the severity of 
the disease. Furthermore, they all involve as key component HIF-1ǂ (Fig. 2), so its targeting 
provides an attractive strategy to treat hypoxic and highly angiogenic tumours like HCC. 
Combination of HIF-1ǂ inhibitors with existing treatments or new targeted therapies like 
sorafenib may prove to be beneficial for the treatment of the disease. 
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